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Letters to the EditorLower incidence of hepatocellular carcinoma in patients
with transient virologic response to peginterferon and
ribavirin combination therapy: Is it really the effect of the therapy?838 Journal of Hepatology 20substitutions in the HCV core region are reportedly associated
with the development of HCC, even in patients who achieved
SVR [9]. Ogawa et al. reported, without providing detailed data,
a higher incidence of HCC in patients bearing the non-TT geno-
type of rs8099917 near the IL28B gene, which is unfavorable to
response to the combination therapy; this observation is also
consistent with our previous report [10].
These results suggest that differences in HCC incidence based
on the outcome of antiviral combination therapy are mainly
attributable to these viral and host factors. It is possible that Oga-
wa et al. simply classiﬁed patients based on the likelihood of
developing HCC upon observing the response to the combination
therapy (i.e., TVR and NVR). It would be interesting if the authors
were to analyze the incidence of HCC in relation to the outcome
of combination therapy based on these host and viral factors. In
addition, it would be interesting to investigate genetic polymor-
phisms near the IL28B gene and amino acid substitutions at res-
idue 70 of the HCV core region, in the 13 patients who developed
HCC despite the achievement of SVR.
Given the existence of factors associated with both therapeu-
tic response and incidence of HCC, one should be cautious in
drawing the conclusion that lower incidence of HCC in patients
with TVR, relative to those with NVR, actually reﬂects the ‘‘sup-
pressive effect’’ of peginterferon and ribavirin combination ther-
apy on hepatocarcinogenesis.
Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.To the Editor:
Ogawa et al. reported interesting and important ﬁndings, based
on a large prospective cohort, regarding the effect of combination
therapy with peginterferon and ribavirin on the incidence of
hepatocellular carcinoma (HCC) [1]. They reported lower inci-
dence of HCC after treatment in patients with transient virologi-
cal response (TVR, deﬁned as relapse or breakthrough), as well as
in patients with sustained virological response (SVR), relative to
patients with non-virological response (NVR). The suppressive
effect of this antiviral therapy on the development of HCC in
patients with SVR has been established by several reports and
can be explained by the eradication of hepatitis C virus (HCV),
resulting in the release of inﬂammation and improvement of liver
ﬁbrosis [2]. However, it is unclear why the incidence of HCC after
treatment was also lower in patients with TVR than in those with
NVR, despite the persistence of viremia after treatment. Ogawa
et al. attributed this observation to the preventive effect of com-
plete HCV suppression during therapy on the development of
HCC.
Previously reported viral and host factors that are strongly
associated with response to antiviral therapy with peginterferon
and ribavirin [3,4] may also be associated with the pathogenesis
of HCC. Amino acid substitutions in the HCV core region, a viral
factor reportedly associated with the response to peginterferon
and ribavirin therapy in patients with HCV genotype 1b [3] (i.e.,
the vast majority of subjects in the study by Ogawa et al.), are also
associated with the development of HCC [5]. Regarding host fac-
tors associated with the response to combination therapy [4],
genetic polymorphisms near the IL28B gene are reportedly asso-
ciated with hepatic steatosis [6] and interact with amino acid
substitutions in the HCV core region [5,7]. Both hepatic steatosis
and amino acid substitutions in the HCV core region are associ-
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To the Editor:
We appreciate the interest shown in our study by Toyoda et al.
and thank them for their comments [1]. Due to space limitations,
we were unable to report extensive details of viral and host fac-
tors, including hepatitis C virus (HCV) core protein and interleu-
kin 28B (IL28B) genotype. We fully agree that the amino acid (aa)
substitutions at position 70 in the HCV core region are associated
with poor virological response to pegylated interferon a (PegIFN-
a) and ribavirin (RBV) treatment, hepatic steatosis, insulin resis-
tance, and development of hepatocellular carcinoma (HCC). We
also previously reported that the diversity of the HCV core region
is signiﬁcantly correlated with abnormal alanine aminotransfer-
ase (ALT) levels [2]. Unfortunately, we do not have information
on the HCV core antigen sequence of the studied patients because
this was a multicenter study that was started before publication
of the ﬁndings of oncogenic potential by treatment-resistant sub-
stitution of core aa 70 (glutamine/histidine) [3]. Although substi-
tutions in the core region might affect the development of HCC,
analysis of a ﬁxed condition such as this, is difﬁcult because the
sequence of the core region sometimes changes with time [4]
or during antiviral treatment [5]. Recently, deep sequencing has
become available for the determination of viral genetic varia-
tions. According to this technology, treatment-resistant substitu-
tion of core aa 70 was found to be contained in most cases, even
when not detected by direct sequencing. The structural and func-
tional alterations of core protein and the relation to the occur-
rence of HCC need to be further studied.
We reported that the incidence rate of HCC for patients with
IL28B TT (rs8099917) genotype after antiviral treatment was sig-
niﬁcantly lower than that for patients with non-TT genotype, as
Journal of Hepatology 20[7] Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common
variation of IL28 affects gamma-GTP levels and inﬂammation of the liver in
chronically infected hepatitis C virus patients. J Hepatol 2010;53:439–443.
[8] Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with
increased frequency of hepatocellular carcinoma in patients with hepatitis
C-related cirrhosis. Cancer 2007;109:2490–2496.
[9] Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino
acid substitutions in hepatitis C virus core region predict hepatocarcino-
genesis following eradication of HCV RNA by antiviral therapy. J Med Virol
2011;83:1016–1022.
[10] Toyoda H, Kumada T. Incidence of hepatocellular carcinoma and response to
interferon therapy in HCV-infected patients: effect of factors associated with
the therapeutic response and incidence of HCC. Liver Int 2012;32:
1029–1031.
JOURNAL OF HEPATOLOGYepatocellular ca
c response to pe
erapy: Is it really
rapy?’’
Toyoda et al. reported [6]. Howe
ference in the incidence rate o
received antiviral treatment be
genotypes [4], despite the fact
was related to treatment-resist
Therefore, further studies are n
nisms related to HCV core aa 70
opment of HCC.
We concluded that transient
associated with a lower risk of d
son with the non-virological re
study and emphasized that thi
only for cirrhotic patients, but al
60 years and over. We did not
directly reducing HCC developm
the possibility of the efﬁcacy of
previous studies. In addition,
redounded to benign clinical ou
showed that the percentage of TV
tic decompensation was lower
Morgan et al. showed similar ﬁn
the rate of biochemical response
after the antiviral treatment) of T
that of NVR (36.2% vs. 17.1%, p <
logical response (non-SVR) patie
ute to the inhibition of the deve
study showed that the HCC inci
icantly lower than that of non
p <0.05). We previously reported
ments by transient elastograp
13 vol. 58 j 831–843rcinoma in
ginterferon
the effect
ver, there was no signiﬁcant dif-
f HCC in patients who had not
tween the IL28B TT and non-TT
that the IL28B non-TT genotype
ant substitution of core aa 70.
eeded to determine the mecha-
, IL28B genotype, and the devel-
virological response (TVR) was
evelopment of HCC in compari-
sponse (NVR) in a prospective
s association was observed not
so for non-cirrhotic patients aged
merely suggest that TVR was
ent. In our discussion, we stated
viral suppression compared with
TVR patients have sometimes
tcomes. For instance, our study
R patients who developed hepa-
than that of NVR patients, and
dings to our study [7]. Moreover,
(BR; ALT <30 IU/L at six months
VR was signiﬁcantly higher than
0.001). BR in non-sustained viro-
nts has been reported to contrib-
lopment of HCC [8]. In fact, our
dence rate of BR/TVR was signif-
-BR/TVR patients (0.9% vs. 6.2%,
that the liver stiffness measure-
hy (FibroScan) of BR/non-SVR
839
